Bellicum Pharmaceuticals, Inc. (BLCM)
| Market Cap | 28.24M |
| Revenue (ttm) | 5.13M |
| Net Income (ttm) | -67.57M |
| Shares Out | 5.06M |
| EPS (ttm) | -11.02 |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Dividend Yield | n/a |
| Trading Day | February 26 |
| Last Price | $4.52 |
| Previous Close | $4.47 |
| Change ($) | 0.05 |
| Change (%) | 1.12% |
| Day's Open | 4.56 |
| Day's Range | 4.22 - 4.69 |
| Day's Volume | 155,941 |
| 52-Week Range | 2.62 - 9.56 |
HOUSTON, Jan. 28, 2021 (GLOBE NEWSWIRE) -- Bellicum Pharmaceuticals, Inc. (NASDAQ:BLCM), a leader in developing novel, controllable cellular immunotherapies for cancers, today announced that t...
Want to try some out-of-the-box approach? Tap five stocks with increasing P/E ratios.
Bellicum Pharmaceuticals (BLCM) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.
Tap five stocks with increasing P/E ratios to try out an out-of-the-box approach.
HOUSTON, Dec. 10, 2020 (GLOBE NEWSWIRE) -- Bellicum Pharmaceuticals, Inc. (NASDAQ:BLCM), a leader in developing novel, controllable cellular immunotherapies for cancers, today announced enroll...
HOUSTON, Dec. 07, 2020 (GLOBE NEWSWIRE) -- Bellicum Pharmaceuticals, Inc. (NASDAQ:BLCM), a leader in developing novel, controllable cellular immunotherapies for cancers, today announced that i...
Although the masses and most of the financial media blame hedge funds for their exorbitant fee structure and disappointing performance, these investors have proved to have great stock picking ...
Bellicum Pharmaceuticals (BLCM) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).
Want to try an out-of-the-box approach? Tap five stocks with increasing P/E ratios.
Strategic focus on clinical GoCAR-T ® programs with plans to initiate Phase 1/2 enrollment of BPX-601 in mCRPC and BPX-603 in HER2+ solid tumors by end of year
HOUSTON, Nov. 03, 2020 (GLOBE NEWSWIRE) -- Bellicum Pharmaceuticals, Inc. (Nasdaq:BLCM), a leader in developing novel, controllable cellular immunotherapies for cancers, today announced the cl...
Shares of Bellicum Pharmaceuticals Inc. plunged 35.1% in midday trading Friday, putting them on track for their biggest-ever one-day drop, after the clinical stage biopharmaceutical company sa...
HOUSTON, Oct. 29, 2020 (GLOBE NEWSWIRE) -- Bellicum Pharmaceuticals, Inc. (Nasdaq:BLCM), a leader in developing novel, controllable cellular immunotherapies for cancers, today announced the pr...
HOUSTON, Oct. 29, 2020 (GLOBE NEWSWIRE) -- Bellicum Pharmaceuticals, Inc. (NASDAQ:BLCM), a leader in developing novel, controllable cellular immunotherapies for cancers, today announced interi...
HOUSTON, Sept. 30, 2020 (GLOBE NEWSWIRE) -- Bellicum Pharmaceuticals, Inc. (NASDAQ:BLCM), a leader in developing novel, controllable cellular immunotherapies for cancers, today announced equit...
HOUSTON, Sept. 28, 2020 (GLOBE NEWSWIRE) -- Bellicum Pharmaceuticals, Inc. (NASDAQ:BLCM), a leader in developing novel, controllable cellular immunotherapies for cancers, today announced that ...
Bellicum Pharmaceuticals' stock continues to be pounded into submission by the market. Now that the market has obliterated any premium left in the stock, I am looking to accumulate.
HOUSTON, Sept. 02, 2020 (GLOBE NEWSWIRE) -- Bellicum Pharmaceuticals, Inc. (NASDAQ:BLCM), a leader in developing novel, controllable cellular immunotherapies for cancers, today announced tha...
Bellicum Pharmaceuticals, Inc. (BLCM) CEO Richard Fair on Q2 2020 Results - Earnings Call Transcript
Bellicum Pharmaceuticals, Inc. (BLCM) CEO Richard Fair on Q2 2020 Results - Earnings Call Transcript
Management to host webcast and conference call on Thursday, August 6, 2020 at 5 p.m. ET / 2 p.m. PT Management to host webcast and conference call on Thursday, August 6, 2020 at 5 p.m. ET / ...
HOUSTON, June 15, 2020 (GLOBE NEWSWIRE) -- Bellicum Pharmaceuticals, Inc. (NASDAQ:BLCM), a leader in developing novel, controllable cellular immunotherapies for cancers, today announced clea...
Top Ranked Momentum Stocks to Buy for June 1st
HOUSTON, May 27, 2020 (GLOBE NEWSWIRE) -- Bellicum Pharmaceuticals, Inc. (NASDAQ:BLCM), a leader in developing novel, controllable cellular immunotherapies for cancers, today announced the p...
Bellicum Pharmaceuticals (BLCM) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #1 (Strong Buy).
HOUSTON, April 30, 2020 (GLOBE NEWSWIRE) -- Bellicum Pharmaceuticals, Inc. (NASDAQ:BLCM), a leader in developing novel, controllable cellular immunotherapies for cancers, today announced equ...
Purchase price of $15 million from sale of manufacturing, office and laboratory facility
Bellicum Pharmaceuticals, Inc. (BLCM) CEO Richard Fair on Q4 2019 Results - Earnings Call Transcript
Bellicum Pharmaceuticals, Inc. (BLCM) CEO Richard Fair on Q4 2019 Results - Earnings Call Transcript
Bellicum Pharmaceuticals (BLCM) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
HOUSTON, Feb. 28, 2020 (GLOBE NEWSWIRE) -- Bellicum Pharmaceuticals, Inc. (NASDAQ:BLCM), a leader in developing novel, controllable cellular immunotherapies for cancers, today announced equi...
HOUSTON, Feb. 05, 2020 (GLOBE NEWSWIRE) -- Bellicum Pharmaceuticals, Inc. (Nasdaq: BLCM) (“Bellicum” or the “Company”), a leader in developing novel, controllable cellular immunotherapies fo...
HOUSTON, Jan. 31, 2020 (GLOBE NEWSWIRE) -- Bellicum Pharmaceuticals, Inc. (NASDAQ:BLCM), a leader in developing novel, controllable cellular immunotherapies for cancers and orphan inherited ...
HOUSTON, Jan. 24, 2020 (GLOBE NEWSWIRE) -- Bellicum Pharmaceuticals, Inc. (NASDAQ:BLCM), a leader in developing novel, controllable cellular immunotherapies for cancers, today presented new ...
Houston manufacturing facility and portions of Bellicum’s Technical Operations and Quality staff to be acquired by MD Anderson
Bellicum’s proprietary technology licensed for use in CD19 CAR NK program Bellicum’s proprietary technology licensed for use in CD19 CAR NK program
iMC activation enhances innate NK cell cytotoxicity against tumor cell lines in vitro
Bellicum Pharmaceuticals, Inc. (BLCM) CEO Rick Fair on Q3 2019 Results - Earnings Call Transcript
Bellicum Pharmaceuticals (BLCM) delivered earnings and revenue surprises of -1.75% and -65.67%, respectively, for the quarter ended September 2019. Do the numbers hold clues to what lies ahead...
Bellicum Pharmaceuticals (BLCM) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
HOUSTON, Sept. 30, 2019 (GLOBE NEWSWIRE) -- Bellicum Pharmaceuticals, Inc. (NASDAQ:BLCM), a leader in developing novel, controllable cellular immunotherapies for cancers and orphan inherited...
The stock has gained 20% since Baker Bros. disclosed its stake in the company.
Bellicum has produced some solid trial data for its lead therapy candidate BPX-501 in pediatric HSCT patients.
HOUSTON, Aug. 28, 2019 (GLOBE NEWSWIRE) -- Bellicum Pharmaceuticals, Inc. (NASDAQ:BLCM), a leader in developing novel, controllable cellular immunotherapies for cancers and orphan inherited ...
Closing of $57.5 Million Public Offering of Preferred Stock and Warrants and Receipt of $12.1 Million Option Fee Related to Private Placement of up to $70.0 Million of Preferred Stock and Warr...
Bellicum Pharmaceuticals (BLCM) delivered earnings and revenue surprises of -7.41% and 497.00%, respectively, for the quarter ended June 2019. Do the numbers hold clues to what lies ahead for ...
Bellicum Pharmaceuticals (BLCM) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Bellicum recently publicized Rivo-cel hit the primary endpoint of event-free survival rate at 180 days of 90.9% in their BP-004 European registrational study.
Bellicum Pharmaceuticals recently reported promising data for BPX-601 at ASCO. The company's GoCAR-T program is taking aim at solid tumors and could be a leading therapy if approved.
Bellicum Pharmaceuticals (BLCM) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Bellicum Pharmaceuticals (BLCM) delivered earnings and revenue surprises of 1.79% and 158.00%, respectively, for the quarter ended March 2019. Do the numbers hold clues to what lies ahead for ...
Bellicum Pharmaceuticals, Inc. announces its next round of earnings this Tuesday, March 12.
About BLCM
Bellicum Pharmaceuticals, a clinical-stage biopharmaceutical company, focuses on discovering and developing novel cellular immunotherapies for the treatment of hematological cancers and solid tumors in the United States and internationally. The company's clinical product candidates include BPX-601, an autologous GoCAR-T product candidate, which is in Phase 1/2 clinical trials for the treatment of solid tumors expressing the prostate stem cell antigen; and BPX-603, a dual-switch GoCAR-T product candidate that is in Phase 1/2 clinical trials to t... [Read more...]
| Industry Biotechnology | IPO Date Dec 18, 2014 |
| CEO Richard Fair | Employees 107 |
| Stock Exchange NASDAQ | Ticker Symbol BLCM |
Financial Performance
In 2019, BLCM's revenue was $7.14 million, an increase of 537.77% compared to the previous year's $1.12 million. Losses were -$112.48 million, 14.7% more than in 2018.
Analyst Forecasts
According to 3 analysts, the average rating for BLCM stock is "Buy." The 12-month stock price forecast is 4.50, which is a decrease of -0.44% from the latest price.